Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Capecitabine and Toripalimab Maintenance in NPC
NCT05869227Phase 3Active, not recruiting
- Start
- Apr 2023
- Primary completion
- Dec 2027
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of capecitabine in nasopharyngeal carcinoma (NPC). Started Apr 2023; status: active, not recruiting.
02
Drugs
capecitabine
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on NCT05869227.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05869227.